Table 4.
AGENT | ROUTE | STATUS (AT TIME OF WRITING) |
---|---|---|
Tedizolid | Oral or IV | Received NOC; not yet marketed |
Ceftobiprole medocaril | IV | Received NOC; never marketed |
Ceftaroline | IV | Not available |
Dalbavancin | IV (weekly) | Not available |
Oritavancin | IV (1-time dose) | Not available |
IV—intravenous, MRSA—methicillin-resistant Staphylococcus aureus, NOC—Health Canada Notice of Compliance.